Sonia Leonardelli
Overview
Explore the profile of Sonia Leonardelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giordano F, Layer J, Leonardelli S, Friker L, Turiello R, Corvino D, et al.
Nat Commun
. 2024 May;
15(1):4210.
PMID: 38806504
The chemokine CXCL12 promotes glioblastoma (GBM) recurrence after radiotherapy (RT) by facilitating vasculogenesis. Here we report outcomes of the dose-escalation part of GLORIA (NCT04121455), a phase I/II trial combining RT...
2.
Giraulo C, Turiello R, Orlando L, Leonardelli S, Landsberg J, Belvedere R, et al.
Biomed Pharmacother
. 2023 Jul;
165:115225.
PMID: 37517292
CD73 is the key enzyme in the generation of extracellular adenosine, a mediator involved in tumor progression, tumor immune escape and resistance to anti-cancer therapeutics. Microenvironmental conditions influence the expression...
3.
Nascentes Melo L, Herrera-Rios D, Hinze D, Loffek S, Oezel I, Turiello R, et al.
J Immunother Cancer
. 2023 Apr;
11(4).
PMID: 37028818
Background: Immune responses against tumors are subject to negative feedback regulation. Immune checkpoint inhibitors (ICIs) blocking Programmed cell death protein 1 (PD-1), a receptor expressed on T cells, or its...
4.
Kramer B, Nalin A, Ma F, Eickhoff S, Lutz P, Leonardelli S, et al.
Cell Rep
. 2023 Jan;
42(1):111937.
PMID: 36640314
Group 1 innate lymphoid cells (ILCs) comprise a heterogeneous family of cytotoxic natural killer (NK) cells and ILC1s. We identify a population of "liver-type" ILC1s with transcriptional, phenotypic, and functional...
5.
Ng S, Leonardelli S, Holzel M
Signal Transduct Target Ther
. 2021 Nov;
6(1):394.
PMID: 34764260
No abstract available.
6.
Esser L, Branchi V, Leonardelli S, Pelusi N, Simon A, Klumper N, et al.
Front Oncol
. 2020 Oct;
10:1775.
PMID: 33072556
Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer accounting for 80% of all renal cancers as well as the majority of renal cancer-associated deaths. During the...
7.
Pieper N, Zaremba A, Leonardelli S, Harbers F, Schwamborn M, Lubcke S, et al.
Oncoimmunology
. 2018 Sep;
7(8):e1450127.
PMID: 30221038
The profound but frequently transient clinical responses to BRAF inhibitor (BRAFi) treatment in melanoma emphasize the need for combinatorial therapies. Multiple clinical trials combining BRAFi and immunotherapy are under way...
8.
Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank K, Paschen A
J Natl Cancer Inst
. 2018 Jun;
110(6):677-681.
PMID: 29917141
Poor clinical responses to checkpoint blockade with anti-CTLA-4 and anti-PD-1 antibodies in melanoma have recently been associated with acquired IFNγ resistance that protects tumor cells from the antiproliferative and pro-apoptotic...
9.
Scholz S, Moller I, Reis H, Susskind D, van de Nes J, Leonardelli S, et al.
Invest Ophthalmol Vis Sci
. 2017 Jul;
58(9):3464-3470.
PMID: 28700778
Purpose: The most common malignant intraocular tumors with a high mortality in adults are uveal melanomas. Uveal melanomas arise most frequently in the choroid or ciliary body (97%) and rarely...